Jubilant Pharmova Share News - Latest Updates, Live News & More

Latest news about Jubilant Pharmova

Jubilant Pharmova Receives ₹22.10 Crore Tax Demand from Income Tax Department for FY2020 8 days ago

Jubilant Pharmova Limited received a ₹22.10 crore tax demand order from the Income Tax Department for FY2020, citing arithmetical errors, expense disallowances, and transfer pricing adjustments. The company plans to file rectification applications and appeals, expecting relief from authorities with no anticipated material financial impact.

Jubilant Pharmova invests CAD 30,000 in Canadian subsidiary for market expansion 9 days ago

Jubilant Pharmova Subsidiary Receives ₹1.73 Crore GST Demand Order from Roorkee Authorities Dec 27, 2025

Jubilant Pharmova's Subsidiary Faces Rs 13.77 Crore GST Demand; Company to Contest Order Dec 05, 2025

Jubilant Pharmova's Montreal Facility Completes USFDA Audit with 9 Observations Nov 04, 2025

More news about Jubilant Pharmova

31Oct 25

Jubilant Pharmova Grants 1,506 Stock Options to Employees, Strengthening Long-Term Commitment

Jubilant Pharmova's Board has approved the grant of 1,506 stock options/RSUs to eligible employees under the 2018 Employees Stock Option Plan. The options have an exercise price of Re. 1.00 each, equal to the face value per equity share. They will vest over 3 years and can be exercised within 1 year of vesting. This move aims to align employee interests with long-term corporate goals and potentially enhance motivation, productivity, and talent retention.

31Oct 25

Jubilant Pharmova Reports Q2 FY26 Results and Completes API Business Transfer

Jubilant Pharmova has announced its Q2 and H1 FY26 financial results, highlighting the completion of its API business transfer to Jubilant Biosys Limited on September 1, 2025. The transfer resulted in accounting changes, including the classification of API business as discontinued operations in standalone results. The company recorded a reversal of deferred tax liability of ₹840 million and created a tax provision of ₹436 million. Consolidated results included exceptional items such as a ₹217 million gain from asset sales in Maryland and ₹179 million in expenses related to temporary suspension of Montreal facility operations. The company's continuing operations now primarily comprise management and support services.

10Oct 25

Jubilant Pharmova Arm Plans $300 Million US Investment to Double Sterile Injectable Capacity by FY28

Jubilant HollisterStier LLC, a subsidiary of Jubilant Pharmova, plans to invest $300 million by FY28 to double its sterile injectable manufacturing capacity in Spokane, Washington. The expansion will increase annual production from 50 million to 100 million vials, addressing a significant demand-supply gap in the US market. The first phase includes a $132 million investment for a third sterile fill and finish line featuring advanced isolator technology. This strategic move is supported by increased demand for US-based manufacturing and a $150 million US government grant. The expansion aims to strengthen the company's position in North American pharmaceutical contract manufacturing and contribute to the US pharmaceutical supply chain's resilience.

01Oct 25

Jubilant Pharmova to Acquire API Business from Jubilant Biosys for ₹595.59 Crore

Jubilant Pharmova has approved the acquisition of Jubilant Biosys's API business for ₹595.59 crore. The deal involves distributing 5,15,59,030 Optionally Convertible Redeemable Preference Shares (OCRPS) valued at ₹515.59 crore and an additional cash payment of ₹80.00 crore. This strategic move aims to strengthen Jubilant Pharmova's position in the Active Pharmaceutical Ingredients market, potentially enhancing its product portfolio and manufacturing capabilities.

23Sept 25

Jubilant Pharmova Appoints Arun Kumar Sharma as Interim CFO

Jubilant Pharmova Limited has appointed Arun Kumar Sharma as interim Chief Financial Officer (CFO) and Key Managerial Personnel (KMP), effective October 1, 2025. The Board of Directors approved the appointment on September 23, 2025. Sharma, with over 30 years of experience in finance, previously held CFO positions within the Jubilant Bhartia Group. His appointment is temporary while the company searches for a permanent CFO. Sharma's expertise includes corporate finance, global treasury, investor relations, and risk management.

20Sept 25

Jubilant Pharmova's US Subsidiary Aces USFDA Pharmacovigilance Inspection

Jubilant Pharmova Limited's subsidiary, Jubilant Cadista Pharmaceuticals Inc., USA, successfully completed a USFDA Post-marketing Adverse Drug Experience (PADE) inspection on September 19, 2025, with no observations. This outcome reaffirms the company's commitment to maintaining high quality and safety standards in the pharmaceutical industry. Jubilant Pharmova, a global pharmaceutical company, operates in various segments including Radiopharma, Allergy Immunotherapy, CDMO, CRDMO, and Generics and Proprietary Novel Drugs.

07Aug 25

Jubilant Pharmova to Meet Institutional Investors in Virtual Conference

Jubilant Pharmova Limited will participate in the NBIE Virtual Investor Conference on August 13, 2025, engaging with eight prominent investment firms. The company operates across various pharmaceutical segments, including radiopharmaceuticals, allergy immunotherapy, and CDMO sterile injectables. Jubilant Pharmova reported recent quarterly revenue of Rs. 1,901.00 crores with an EBITDA margin of 15.80%. The company has set ambitious Vision 2030 targets, aiming to double revenue, achieve 23-25% EBITDA margins, reach zero net debt, and attain high teens return on capital employed.

02Aug 25

Jubilant Pharmova's Roorkee Facility Completes USFDA Pre-Approval Inspection with 4 Observations

Jubilant Pharmova announced the completion of a USFDA pre-approval inspection at its Roorkee solid dosage formulations facility, operated by subsidiary Jubilant Generics Limited. The inspection, concluded on August 1, 2025, resulted in four observations. The company plans to submit an action plan to address these. Notably, the Roorkee site's US market revenue represents less than 1% of Jubilant Pharmova's total revenues for the July 2024 to June 2025 period.

01Aug 25

Jubilant Pharmova Reports 10% Revenue Growth, Schedules Investor Meetings in Singapore

Jubilant Pharmova reported a 10% year-over-year revenue growth to Rs. 1,901.00 crores for Q1 FY26. EBITDA increased by 14% to Rs. 302.00 crores, with margins improving to 15.8%. Normalized PAT grew by 48% to Rs. 103.00 crores. All business segments showed growth, with Radiopharmaceuticals generating Rs. 869.00 crores in revenue. The company announced upcoming investor meetings in Singapore on August 6, 2025, as part of the Nuvama India Conference, where it will meet with nine institutional investors. Jubilant Pharmova's Vision 2030 aims to double revenue, achieve 23-25% EBITDA margins, reach zero net debt, and attain high teens return on capital employed.

29Jul 25

Jubilant Pharmova CFO Arvind Chokhany to Step Down by September 30, 2025

Jubilant Pharmova announced the resignation of CFO and Whole-Time Director Arvind Chokhany, effective September 30, 2025. The company reported strong Q2 results with a 10% increase in consolidated revenue to ₹19,007.00 crore, 14% growth in EBITDA to ₹3,020.00 crore, and a 48% rise in normalized PAT to ₹1,030.00 crore. Segment performances varied, with CRDMO (Drug Discovery) showing the highest growth at 42%.

29Jul 25

Jubilant Pharmova Reports Strong Q1 Results with 10% Revenue Growth and Improved Profitability

Jubilant Pharmova Limited announced Q1 financial results showing robust growth. Consolidated revenue increased 9.8% to ₹19,007.00 crore. Profit before tax and exceptional items rose 48.7% to ₹1,544.00 crore. Net profit stood at ₹1,025.00 crore. Radiopharma remained the largest revenue contributor. CDMO - Sterile Injectables and CRDMO segments showed significant growth. Segment-wise profitability varied, with CRDMO doubling its profit and Generics reducing losses substantially. The company's financial position remains strong with total assets of ₹130,033.00 crore.

13Jun 25

Jubilant Pharmova Shares See Massive Block Trade Worth Rs. 512 Crore on NSE

A large block trade of approximately 4,804,883 shares of Jubilant Pharmova Ltd. occurred on the National Stock Exchange (NSE). The transaction, valued at Rs. 511.96 crore, was executed at Rs. 1,065.50 per share. This significant trade indicates potential changes in the company's ownership structure and provides a reference point for market valuation. Jubilant Pharmova, a key player in the Indian pharmaceutical sector, operates in contract research and development services, proprietary novel drugs, and radiopharmaceuticals.

13Jun 25

Jubilant Pharmova to Transfer API Business to Wholly Owned Subsidiary

Jubilant Pharmova Limited's board has approved the sale and transfer of its Active Pharmaceutical Ingredients (API) business to Jubilant Biosys Limited, a wholly owned subsidiary. The transfer will be executed on a slump sale basis, involving the entire business unit as a going concern. This strategic move aims to streamline operations, enhance focus on the API segment, and potentially drive growth opportunities.

12Jun 25

Jubilant Pharmova to Transfer API Division to Wholly Owned Subsidiary

Jubilant Pharmova's board has approved the transfer of its Active Pharmaceutical Ingredients (API) division to its wholly owned subsidiary, Jubilant Biosys Limited. The transfer will be executed as a slump sale, with the API division reporting a turnover of ₹609.00 crore, representing 8.35% of the company's consolidated revenue. The transfer is expected to be completed by September 1, 2025, with consideration based on the book value of assets and liabilities of the API division.

20Mar 25

Jubilant Pharmova Expands Global R&D Footprint with Strategic Acquisition in France

Jubilant Pharmova's subsidiary, Jubilant Biosys Innovative Research Services Pte Limited, has acquired an 80% stake in JASMIN, now renamed Jubilant Biosys France. This new entity has acquired Pierre Fabre's R&D Centre in Saint Julien, France. Pierre Fabre SA retains a 20% stake in Jubilant Biosys France. The deal, closed on March 19, 2025, enhances Jubilant Pharmova's research infrastructure in Europe, potentially accelerating drug discovery and development processes.

13Mar 25

Jubilant Pharmova's US Subsidiary Clears USFDA Inspection with VAI Status

Jubilant Pharmova's subsidiary, Jubilant Cadista Pharmaceuticals Inc., received an Establishment Inspection Report (EIR) with Voluntary Action Indicated (VAI) status from the USFDA for its Salisbury, Maryland facility. The inspection was conducted in January 2025, and the company was notified on March 11, 2025. Despite this positive outcome, the facility is not expected to manufacture any products in the future, as its operations have been closed, a decision previously announced in April 2024.

12Mar 25

Jubilant Pharmova's US Subsidiary Clears FDA Inspection with VAI Status

Jubilant Cadista Pharmaceuticals Inc., a US subsidiary of Jubilant Pharmova, received an Establishment Inspection Report (EIR) with Voluntary Action Indicated (VAI) status from the FDA for its Salisbury, Maryland facility in January 2025. The inspection concluded satisfactorily, allowing continued operations without major regulatory concerns. However, the company has previously announced the closure of manufacturing operations at this facility, as disclosed in April 2024.